Nu-Med Plus (NUMD) Cash & Equivalents Growth (1y) (2012 - 2025)
Nu-Med Plus (NUMD) Cash & Equivalents Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -7.50% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -22.13% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -7.71% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 20.15% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 23.57% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 156.03% |
| 10 | Nu-Med Plus | - | - | - | -72.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.14% |
| Sep 30, 2025 | -51.79% |
| Jun 30, 2025 | -78.64% |
| Mar 31, 2025 | -62.67% |
| Dec 31, 2024 | -65.13% |
| Sep 30, 2024 | -63.56% |
| Jun 30, 2024 | -86.51% |
| Mar 31, 2024 | -88.01% |
| Dec 31, 2023 | -90.70% |
| Sep 30, 2023 | 1,665.61% |
| Mar 31, 2023 | 1,990.22% |
| Dec 31, 2022 | 526.94% |
| Sep 30, 2022 | -98.03% |
| Mar 31, 2022 | -98.18% |
| Dec 31, 2021 | -93.81% |
| Sep 30, 2021 | 1.09% |
| Jun 30, 2021 | 1,092.78% |
| Mar 31, 2021 | 659.85% |
| Dec 31, 2020 | 2,562.89% |
| Sep 30, 2020 | -24.71% |